Peculiarities of studying the effects of pathogen reduction technologies on platelets

Osman, Abdimajid; Hitzler, W; Provost, Patrick

doi:10.1002/prca.201500124

Cited by 8 publications

(5 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the support of in vitro cell proliferation by HPL prepared from PR-treated platelet concentrates was found to be at least comparable to FBS [ 53 , 54 , 55 , 56 , 57 ]. In contrast, affected platelet metabolism and function and increased storage lesions were observed in platelet concentrates after PR treatment [ 58 , 59 ]. Consequently, efficacy and potency of HPL produced from PR-treated platelet concentrates may be affected, although safety may be increased.…”

Section: Whole Blood Processing and Production Of Platelet Concentratesmentioning

confidence: 99%

Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production

Oeller

Laner-Plamberger

Krisch

et al. 2021

IJMS

View full text Add to dashboard Cite

Numerous cell-based therapeutics are currently being tested in clinical trials. Human platelet lysate (HPL) is a valuable alternative to fetal bovine serum as a cell culture medium supplement for a variety of different cell types. HPL as a raw material permits animal serum-free cell propagation with highly efficient stimulation of cell proliferation, enabling humanized manufacturing of cell therapeutics within a reasonable timeframe. Providers of HPL have to consider dedicated quality issues regarding identity, purity, potency, traceability and safety. Release criteria have to be defined, characterizing the suitability of HPL batches for the support of a specific cell culture. Fresh or expired platelet concentrates from healthy blood donors are the starting material for HPL preparation, according to regulatory requirements. Pooling of individual platelet lysate units into one HPL batch can balance donor variation with regard to essential platelet-derived growth factors and cytokines. The increasingly applied pathogen reduction technologies will further increase HPL safety. In this review article, aspects and regulatory requirements of whole blood donation and details of human platelet lysate manufacturing are presented. International guidelines for raw materials are discussed, and defined quality controls, as well as release criteria for safe and GMP-compliant HPL production, are summarized.

show abstract

Section: Whole Blood Processing and Production Of Platelet Concentratesmentioning

confidence: 99%

Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production

Oeller

Laner-Plamberger

Krisch

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…INTERCEPT, but not MIRASOL PI treatment has been shown to affect the platelet mRNA transcriptome ( 27 , 136 ). However, miRNA synthesis and function were not affected and no cross-linking of miRNA-sized endogenous platelet RNA species was observed; rather miRNA levels were reduced ( 136 , 137 ).…”

Section: The Impact Of Pi On Platelet Functionsmentioning

confidence: 99%

Ultraviolet-Based Pathogen Inactivation Systems: Untangling the Molecular Targets Activated in Platelets

et al. 2018

View full text Add to dashboard Cite

Transfusions of platelets are an important cornerstone of medicine; however, recipients may be subject to risk of adverse events associated with the potential transmission of pathogens, especially bacteria. Pathogen inactivation (PI) technologies based on ultraviolet illumination have been developed in the last decades to mitigate this risk. This review discusses studies of platelet concentrates treated with the current generation of PI technologies to assess their impact on quality, PI capacity, safety, and clinical efficacy. Improved safety seems to come with the cost of reduced platelet functionality, and hence transfusion efficacy. In order to understand these negative impacts in more detail, several molecular analyses have identified signaling pathways linked to platelet function that are altered by PI. Because some of these biochemical alterations are similar to those seen arising in the context of routine platelet storage lesion development occurring during blood bank storage, we lack a complete picture of the contribution of PI treatment to impaired platelet functionality. A model generated using data from currently available publications places the signaling protein kinase p38 as a central player regulating a variety of mechanisms triggered in platelets by PI systems.

show abstract

“…Several studies have unveiled a potential role for human platelet microRNAs in the field of transfusion medicine, in terms of regulating platelet signaling pathways, markers of platelet associated disorders, and remote impactors of gene expression (intercellular biomodulators) as well as potential platelet quality markers of storage and pathogen reduction treatments [83], some of which have been reviewed recently [84].…”

Section: Platelet Transfusionmentioning

confidence: 99%

The clinical significance of platelet microparticle-associated microRNAs

Provost

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

Self Cite

View full text Add to dashboard Cite

Abstract:Circulating blood platelets play a central role in the maintenance of hemostasis. They adhere to subendothelial extracellular matrix proteins that become exposed upon vessel wall damage, which is followed by platelet activation, further platelet recruitment, platelet aggregation and formation of an occlusive, or non-occlusive, platelet thrombus. Platelets host a surprisingly diverse transcriptome, which is comprised of ~ 9500 messenger RNAs (mRNAs) and different classes of non-coding RNAs, including microRNAs, as well as a significant repertoire of proteins that contribute to their primary (adhesion, aggregation, granule secretion) and alternative (RNA transfer, mRNA translation, immune regulation) functions. Platelets have the propensity to release microparticles (MPs; 0.1-1 μm in diameter) upon activation, which may mediate inflammatory responses and contribute to exacerbate inflammatory diseases and conditions. Carrying components of the platelets' cytoplasm, platelet MPs may exert their effects on recipient cells by transferring their content in platelet-derived bioactive lipid mediators, cytokines, mRNAs and microRNAs. Platelet MP-associated microRNAs may thus function also outside of platelets and play an important role in intercellular signaling and gene expression programming across the entire circulatory system. The role and importance of platelet MP-associated microRNAs in various aspects of biology and pathophysiology are increasingly recognized, and now provide the scientific basis and rationale to support further translational research and clinical studies. The clinical significance, pathophysiological role as well as the diagnostic and therapeutic potential of platelet MP-associated microRNAs in cardiovascular diseases, platelet transfusion and cancer will be discussed.

show abstract

Peculiarities of studying the effects of pathogen reduction technologies on platelets

Cited by 8 publications

References 80 publications

Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production

Human Platelet Lysate for Good Manufacturing Practice-Compliant Cell Production

Ultraviolet-Based Pathogen Inactivation Systems: Untangling the Molecular Targets Activated in Platelets

The clinical significance of platelet microparticle-associated microRNAs

Contact Info

Product

Resources

About